Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents

DOI10.1111/RSSC.12294MaRDI QIDQ6642051

Mourad Tighiouart

Publication date: 21 November 2024

Published in: Journal of the Royal Statistical Society. Series C. Applied Statistics (Search for Journal in Brave)

zbMATH Keywords

cubic splinesmaximum tolerated dosedrug combinationescalation with overdose controlBayesian adaptive designcancer phase I--II trials

Mathematics Subject Classification ID

Applications of statistics (62Pxx)

Related Items (2)

A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages ⋮ A nonparametric Bayesian method for dose finding in drug combinations cancer trials

This page was built for publication: Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6642051)